Dr Reddy's launches docetaxel injection in US
The Taxotere (docetaxel injection) brand and generic has US sales of approximately $ 218 million MAT for the most recent twelve months ending in September 2014
The Hyderabad based Dr Reddy’s Laboratories has launched docetaxel injection USP 20 mg/mL and 80 mg/4 mL, a therapeutic equivalent generic version of Taxotere (marketed by Sanofi Aventis), in the US market on November 21, 2014.
The Taxotere brand and generic has US sales of approximately $ 218 million MAT for the most recent twelve months ending in September 2014, according to IMS Health.
Dr Reddy’s docetaxel injection USP, 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does not require a prior dilution with a diluent and is ready to add to the intravenous infusion solution.
The Taxotere brand and generic has US sales of approximately $ 218 million MAT for the most recent twelve months ending in September 2014, according to IMS Health.
Dr Reddy’s docetaxel injection USP, 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does not require a prior dilution with a diluent and is ready to add to the intravenous infusion solution.